Gastroprotective medications
Pro Research Analysisby 
Searched over 200M research papers for "gastroprotective medications"
Types of Gastroprotective Medications and Their Mechanisms
Gastroprotective medications are commonly used to prevent and treat peptic ulcer disease and its complications, especially in patients at risk due to medications like NSAIDs or anticoagulants. The main classes include proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), prostaglandin analogues, and other agents such as sucralfate and natural compounds like glycosaminoglycans and thymol. These drugs work by reducing stomach acid, enhancing mucosal defenses, or both, and some also promote healing of existing ulcers Scally2018Szabó2014Traserra2023+1 MORE.
Efficacy of Gastroprotective Agents in Preventing Ulcers and GI Complications
Large-scale analyses show that gastroprotective drugs significantly reduce the development of endoscopic and symptomatic ulcers, as well as upper gastrointestinal bleeding, but do not have a significant effect on overall mortality. Among these, PPIs are the most effective, followed by H2RAs and prostaglandin analogues. PPIs also show greater efficacy in healing existing ulcers and reducing the risk of further bleeding in acute cases .
In patients using NSAIDs, all major gastroprotective strategies—including PPIs, misoprostol, and COX-2 inhibitors—lower the risk of upper GI complications. The combination of a COX-2 inhibitor with a PPI offers the greatest risk reduction. Celecoxib, a COX-2 inhibitor, may be more effective than combining a nonselective NSAID with a PPI .
Use in Special Populations: Elderly and High-Risk Patients
Guidelines recommend gastroprotective agents for elderly patients (65 years and older) taking NSAIDs, as they are at higher risk for GI ulcers. Observational studies confirm that these agents are effective in this population, but actual prescription rates remain low, with only about 24% of elderly NSAID users receiving gastroprotection. The evidence supports their use, but more clarity is needed on the optimal age and risk factors for starting therapy Medlock2013Thiéfin2011Shabani2020.
Underutilization and Prescribing Patterns
Despite clear benefits, gastroprotective agents are often underprescribed in at-risk patients. Studies show that only about half of NSAID users over 65 receive gastroprotection, and 40% of at-risk users do not get these medications. Prescription is more likely in those with a history of ulcers, GI symptoms, or concurrent use of other gastrotoxic drugs. However, some patients without risk factors also receive these drugs, often due to symptoms like reflux or dyspepsia Thiéfin2011Saldanha2021Shabani2020.
Alternative and Emerging Gastroprotective Strategies
Beyond traditional medications, natural substances such as glycosaminoglycans (GAGs) combined with sodium alginate have shown promise in animal models, providing protection comparable to sucralfate. Thymol, a compound found in certain herbs, also demonstrates gastroprotective effects by increasing mucus production and involving prostaglandin pathways Traserra2023Ribeiro2016.
Gastroprotection in Patients on Anticoagulants
For patients taking dabigatran, a blood thinner, the use of gastroprotective agents (PPIs or H2RAs) is associated with a reduced risk of gastrointestinal bleeding, especially in those with a history of ulcers or GI bleeding. The protective effect is more pronounced for upper GI bleeding .
Mechanisms of Action and Ongoing Research
Gastroprotection involves complex mechanisms, including increased mucus and bicarbonate secretion, enhanced vascular permeability, and the action of endogenous substances like prostaglandins and sulfhydryls. While much is understood, research continues to uncover new pathways and agents that may offer safer or more effective protection, especially for patients who cannot tolerate current therapies or have Helicobacter pylori-negative ulcers .
Conclusion
Gastroprotective medications, particularly PPIs, are highly effective in preventing and treating peptic ulcers and reducing GI complications in high-risk patients, such as those on NSAIDs or anticoagulants. However, these agents remain underutilized in many at-risk populations. Newer and alternative therapies are being explored, but optimizing the use of established medications remains a key priority for improving patient outcomes.
Sources and full results
Most relevant research papers on this topic
Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies.
Gastroprotective agents are effective in preventing NSAID-associated gastrointestinal events in elderly patients, but more research is needed to determine optimal age for prescribing.
DOI
Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs.
Gastroprotection is largely underprescribed in patients at risk of gastrointestinal complications from non-steroidal anti-inflammatory drugs in France, with only half of users over 65 years old receiving such agents.
DOI